Clinical Trials Logo
  1. Home
  2. Cocaine-Related Disorders
  3. NCT00000323
  4. Details
NCT00000323 Clinical Trial

Therapeutic Potential of Kappa-Opioids Against Cocaine - 1

Cocaine-Related Disorders Clinical Trial

Official title:
Therapeutic Potential of Kappa-Opioids Against Cocaine

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT00000323
Other study ID # NIDA-10753-1
Secondary ID R01-10753-1
Status Completed
Phase Phase 1
First received September 20, 1999
Last updated January 11, 2017
Start date July 1996
Est. completion date December 1998

Study information
Verified date May 2004
Source National Institute on Drug Abuse (NIDA)
Contact n/a
Is FDA regulated No
Health authority United States: Federal Government
Study type Observational

Clinical Trial Summary

The purpose of this study is to characterize the effects of enadoline compared to hydromorphone and butorphanol.

Recruitment information / eligibility
Status Completed
Enrollment 10
Est. completion date December 1998
Est. primary completion date
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 21 Years to 50 Years
Eligibility Inclusion Criteria:

opiate experienced, healthy

Exclusion Criteria:

physical dependence on opioids, barbiturates or alcohol

Study Design

N/A

Related Conditions & MeSH terms

Locations
Country Name City State
United States Johns Hopkins University (BPRU) Bayview Campus Baltimore Maryland

Sponsors (1)
Lead Sponsor Collaborator
National Institute on Drug Abuse (NIDA)

Country where clinical trial is conducted

United States, 

References & Publications (1)

Walsh SL, Strain EC, Abreu ME, Bigelow GE. Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans. Psychopharmacology (Berl). 2001 Sep;157(2):151-62. — View Citation

See also
  Status Clinical Trial Phase
Completed NCT01526538 - Improving Learning-based Treatment of Cocaine Dependence With Medication Phase 2
Completed NCT00877435 - Prize Reinforcement Contingency Management for Cocaine Dependence: a 24-week Randomized Controlled Trial N/A
Completed NCT00430690 - Acoustic Startle Reduction In Cocaine Dependence
Completed NCT00217997 - Impulsivity, Brain Function, and Substance Abuse Treatment in Cocaine Dependent Individuals N/A
Active, not recruiting NCT00094315 - Development of Human Laboratory Study Model of Cocaine Relapse Prevention II - 1 Phase 1
Terminated NCT00142883 - The Effects of GABA Enhancing Medications on Individuals Addicted to Cocaine - 3 N/A
Completed NCT00218348 - Treatment of Cocaine Dependence: Comparison of Three Doses of Dextro-Amphetamine Sulfate and Placebo Phase 2
Completed NCT00142844 - Combination of Disulfiram Plus Naltrexone to Treat Both Cocaine- and Alcohol-dependent Individuals - 1 Phase 2
Completed NCT00158132 - Effectiveness of Amantadine and Propranolol for Treating Cocaine Dependence - 2 Phase 2
Completed NCT00000294 - Effects of Carvedilol on Cocaine Use in Humans - 11 Phase 2
Completed NCT00015054 - Methylphendidate Treatment of Cocaine Dependent Patients With Attention Deficit Hyperactivity Disorder - 3 Phase 2
Completed NCT00000308 - Dextroamphetamine-Cocaine Behavioral Intervention - 5 Phase 2
Completed NCT00000306 - Dextroamphetamine as Adjunct in Cocaine/Opiate Dependent Patients - 3 Phase 2
Completed NCT00000280 - Glutaminergic Agents for Cocaine Abuse - 5 Phase 1
Completed NCT00000314 - M-CPP and Fenfluramine in Cocaine Addicts - 3 Phase 2
Completed NCT00000281 - Pharmacotherapy for Schizophrenic Drug Users - 6 Phase 2
Completed NCT00000188 - Selegiline in Treatment of Cocaine Dependence - 2 Phase 2
Completed NCT00000278 - Disulfiram for Cocaine-Alcohol Abuse - 3 Phase 2
Completed NCT00000282 - Pemoline for Cocaine Abuse - 7 Phase 2
Terminated NCT00000276 - Dopamine Reuptake Inhibitors of Cocaine Abuse - 1 Phase 1